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Objective: According to a recent randomized, double-blind clinical trial comparing the com-
bination of voriconazole and anidulafungin (VOR+ANI) with VOR monotherapy for invasive 
aspergillosis (IA) in patients with hematologic disease or with hematopoietic stem cell transplant, 
mortality was lower after 6 weeks with VOR+ANI than with VOR monotherapy in a post hoc 
analysis of patients with galactomannan-based IA. The objective of this study was to compare 
the cost-effectiveness of VOR+ANI with VOR, from the perspective of hospitals in the Spanish 
National Health System.
Methods: An economic model with deterministic and probabilistic analyses was used to deter-
mine costs per life-year gained (LYG) for VOR+ANI versus VOR in patients with galactoman-
nan-based IA. Mortality, adverse event rates, and life expectancy were obtained from clinical 
trial data. The costs (in 2015 euros [€]) of the drugs and the adverse event-related costs were 
obtained from Spanish sources. A Tornado plot and a Monte Carlo simulation (1,000 iterations) 
were used to assess uncertainty of all model variables.
Results: According to the deterministic analysis, for each patient treated with VOR+ANI 
compared with VOR monotherapy, there would be a total of 0.348 LYG (2.529 vs 2.181 years, 
respectively) at an incremental cost of €5,493 (€17,902 vs €12,409, respectively). Conse-
quently, the additional cost per LYG with VOR+ANI compared with VOR would be €15,785. 
Deterministic sensitivity analyses confirmed the robustness of these findings. In the proba-
bilistic analysis, the cost per LYG with VOR+ANI was €15,774 (95% confidence interval: 
€15,763–16,692). The probability of VOR+ANI being cost-effective compared with VOR 
was estimated at 82.5% and 91.9%, based on local cost-effectiveness thresholds of €30,000 
and €45,000, respectively.
Conclusion: According to the present economic study, combination therapy with VOR+ANI 
is cost-effective as primary therapy of IA in galactomannan-positive patients in Spain who have 
hematologic disease or hematopoietic stem cell transplant, compared with VOR monotherapy.
Keywords: anidulafungin, cost-effectiveness, galactomannan, invasive aspergillosis, 
voriconazole
Introduction
Invasive aspergillosis (IA) is a life-threatening infection, particularly in patients 
with hematologic disease or who have received hematopoietic stem cell transplan-
tation (HSCT).1 Although survival has increased in recent years due to advances in 
diagnosis and new antifungal drugs,2 prognosis of IA continues to be suboptimal, 
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with an attributable mortality of 42%–64%.3,4 Combina-
tion therapies may improve antifungal efficacy but do so 
at increased cost.
The public price of treating diagnosis-related group 
number 580 (systemic infections and parasitic disorders 
except septicemia with major complications), which includes 
aspergillosis, has been reported to be €7,173 in Madrid5 and 
€9,072 in Navarra, Spain.6 In a German study published in 
2014, which looked at Spanish hospital data on the cost of 
antifungal therapy of IA, voriconazole (VOR) had a lower 
total treatment cost compared with liposomal amphotericin 
B (€8,032 and €10,516, respectively).7 Given the significant 
health and economic impact of IA, it is extremely important 
to select the most appropriate IA therapy strategy.
Accurate diagnosis of IA is difficult, because the health 
status of the patient often precludes invasive procedures and 
biopsy sampling. Given that early diagnosis is fundamental 
for improving therapeutic outcomes, rapid detection of 
galactomannan antigen in serum or bronchoalveolar lavage 
is useful in the early diagnosis and monitoring of IA.8
According to a recent clinical trial in patients with 
hematologic disease or HSCT, mortality at 6 weeks of IA 
therapy was lower with a combination of voriconazole and 
anidulafungin (VOR+ANI) than with VOR monotherapy and 
was lower in the subgroup of patients receiving combination 
therapy who had probable IA based on positive galactoman-
nan antigen testing than in the overall population of patients 
receiving combination therapy.9 The objective of our study 
was to compare the cost-effectiveness of both therapies, 
from the perspective of hospitals in the Spanish National 
Health System.
Methods
Economic model
Using an economic model, the efficacy of VOR+ANI com-
bination therapy was compared with VOR monotherapy 
for the treatment of IA in a hypothetical cohort of 1,000 
galactomannan-positive patients. The model consisted of a 
decision tree (Figure 1) predicting outcomes after 6 weeks 
of therapy. The analysis considered the following variables: 
mortality or survival rate of the patient; probability of adverse 
events (AEs) occurring or not; probability of any AEs occur-
ring being serious or mild-to-moderate; costs of antifungal 
therapy, AE-related costs, and costs of hospital stays (ward 
and intensive care unit [ICU]); and life expectancy in patients 
with HSCT who respond satisfactorily to antifungal therapy 
for IA. Efficacy and toxicity data were obtained from a 
clinical trial reporting on VOR+ANI combination therapy 
in 108 patients and VOR monotherapy in 110 patients 
(NCT00531479).9
Antifungal therapy for
invasive aspergillosis in
galactomannan-positive
patients
VOR+ANI combination therapy
VOR monotherapy
Death at 6 weeks
Death at 6 weeks
(pMVA)
(pMV)
(1-pMVA)
(1-pMV)
(1-pAEVA)
(1-pAEV)
(1-pSAEVA)
(pSAEVA)
(1-pSAEV)
(pSAEV)
Mild-to-moderate AEs
Mild-to-moderate AEs
Survival at 6 weeks
Survival at 6 weeks
Without AEs
Without AEs
Serious AEs
Serious AEs
With AEs
With AEs
(pAEVA)
(pAEV)
Figure 1 Decision tree model.
Note: 1- Represents the complementary probability.
Abbreviations: AE, adverse event; ANI, anidulafungin; pAEV, probability of AEs occurring with VOR monotherapy; pAEVA, probability of AEs occurring with VOR+ANI 
combination therapy; pMV, probability of mortality with VOR monotherapy; pMVA, probability of mortality with VOR+ANI combination therapy; pSAEV, probability of 
serious AEs occurring with VOR monotherapy; pSAEVA, probability of serious AEs occurring with VOR+ANI combination therapy; VOR, voriconazole.
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The main model inputs are presented in Table 1. Deter-
ministic and probabilistic analyses were conducted. The 
base-case deterministic analysis was constructed using mean 
values for each variable; sensitivity analyses modifying 
each parameter were also performed for all of the variables 
presented in Table 1. Specifically, the sensitivity of the result 
to variation in the following parameters was assessed (for 
VOR+ANI or VOR): probability of mortality, duration of 
hospital stay, life expectancy, drug acquisition cost; prob-
ability of occurrence of mild-to-moderate or serious AEs, and 
costs related to mild-to-moderate or serious AEs. Variation 
in the duration of antifungal therapy (base-case ±7 days) was 
also considered. Probabilistic analysis was conducted using 
second-order Monte Carlo simulations10 (1,000 iterations), 
with the objective of assessing the uncertainty of all variables, 
which is indicated in Table 1. Monte Carlo simulations use 
computerized statistical sampling techniques to obtain a 
probabilistic approximation of the solution of an equation 
or mathematical model.11 The rates were adjusted to beta 
distributions and the costs to gamma distributions.10
The economic model was applied using the TreeAge Pro 
2014 program (TreeAge Software, Inc., Williamstown, MA, 
USA). All prices and costs in the model were expressed in 
2015 euros (€), with the exception of the 7.5% reduction of 
the price of ANI (Ecalta®; Pfizer Inc., NY, USA) in Spain 
that was authorized in early 2016.
Mortality
As shown in Table 1, according to the clinical trial of Marr 
et al,9 mortality after 6 weeks of IA therapy was signifi-
cantly lower with VOR+ANI than with VOR monotherapy 
in galactomannan-positive patients (15.7% and 27.3%, 
respectively; p=0.037).
Adverse events
A serious AE was defined as an event for which the patient 
outcome is death, life-threatening, hospitalization, or per-
manent disabilities or damage, in accordance with guidance 
issued by the US Food and Drug Administration.12 The overall 
AE rate in the galactomannan-positive patient group was 
Table 1 Economic model assumptions
Item Average Intervala SD Distribution Alpha Beta References
Mortality rates, %
VOR+ANI 15.74 10.07–23.77 3.50 Beta 16.93 90.62 Marr et al9
VOR 27.27 19.82–36.26 4.19 30.51 81.35
Treatment-related AEs, %
VOR+ANI 69.74 63.49–75.33 3.02 Beta 160.49 69.65 Marr et al9
VOR 62.39 55.92–68.45 3.20 142.62 85.98
Serious treatment-related AEs, %
VOR+ANI 19.50 14.09–26.34 3.13 Beta 31.12 128.48 Marr et al9
VOR 14.18 9.37–20.90 2.94 19.85 120.06
Antifungal treatment costb €
VOR+ANI 10,899.89 10,817.01–11,126.86 79.04 Gamma 19,015.61 0.57 Ministerio de Sanidad Servicios Sociales e 
Igualdad;16 Consejo General de Colegios 
Oficiales de Farmacéuticos13
VOR 6,054.74 5,971.86–6,281.71 79.04 5,867.56 1.03
Mild to moderate AE unit costc €
Both 457.04 365.64–548.45 46.64 Gamma 96.04 4.76 Ojeda et al;17 Martin-Iglesias;18 Llibre-
Codina et al;19 Presidente de la Gerencia 
Regional de Salud;20 Servicio Madrileño de 
Salud;5 Marr et al9
Serious AE unit costc €
Both 1,859.57 1,487.66–2,231.49 189.75 Gamma 96.04 19.36 Ojeda et al;17 Ministerio de Sanidad 
Servicios Sociales e Igualdad;21 Holstenson 
et al;22 Isla et al;23 Servicio Madrileño de 
Salud;5 Marr et al9
Hospital stay costd €
VOR+ANI 6,815.59 5,126.41–8,728.69 918.95 Gamma 55.01 123.90 Peiró et al;38 Asensio et al;24 Marr et al9
VOR 6,274.84 4,645.32–8,127.05 888.20 49.91 125.72
Life expectancye years
Both 3.00 2.70–3.30 0.15 Gamma 384.16 0.01 Jansen et al;25 Jansen et al;26 Ament et al;27 
Krueger and Nelson28
Notes: aInterval is given as 95% CI unless otherwise indicated; bbody weight in Spanish adults (70.0 kg; 95% CI: 67.76–76.13 kg) obtained from Spanish official figures16; 
ccalculated on the basis of AE with significant cost (NCT00531479); dcalculated from clinical trial data,9 32% of total hospital costs were subtracted as the cost of drugs to 
avoid double-counting;38 elife expectancy of recipients of a hematopoietic stem cell transplant who survive after invasive aspergillosis treatment is ~3 years.25–28 Interval: ±10%.
Abbreviations: AE, adverse event; ANI, anidulafungin; CI, confidence interval; SD, standard deviation; VOR, voriconazole.
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higher with VOR+ANI (69.7%) than with VOR monotherapy 
(62.4%); the rate of serious AEs was also higher (19.5% and 
14.2%, respectively; Table 1).9
Drug acquisition costs
The acquisition costs of VOR (Vfend®; Pfizer Inc.) and ANI 
(Ecalta®) were obtained from the official manufacturer’s sales 
prices in Spain, including the recently authorized mandatory 
discount of 7.5% for ANI (Table 2).13 We also considered the 
dosage schedules recommended in the Summary of Product 
Characteristics of both drugs14,15 and, in the case of VOR, 
the average body weight of adults in Spain (70.0 kg; 95% 
confidence interval [CI]: 67.8–76.1 kg), obtained from Min-
istry of Health databases (Table 2).16 Patients were assumed 
to receive treatment with ANI (200 mg on day 1, followed 
by 100 mg every subsequent day of treatment) for at least 2 
weeks and no more than 4 weeks.
AE-related costs
The costs of serious and mild-to-moderate AEs were calcu-
lated from the rates described by Marr et al9 and from the 
unit costs of handling the AE, obtained from Spanish sources 
(Table 1).5,17–23
Hospitalization costs
The frequencies of hospitalization (within a timeframe of 6 
weeks) with VOR (31.7%) and VOR+ANI (30.4%) on the 
ward and in the ICU were obtained from data reported by 
Marr et al;9 length of hospital stay for VOR+ANI and VOR 
alone in the general ward (36.0 and 34.4 days, respectively) 
and the ICU (14.2 and 13.7 days, respectively) were also 
taken from this clinical trial. Unit costs of a 1-day stay on the 
general ward (€457; 95% CI: €366–548) and ICU (€1,860; 
95% CI: €1,488–2,231) were obtained from a previously 
published Spanish study (Table 1).24
Life expectancy (time horizon)
The life expectancy of patients with HSCT who survive 
after antifungal therapy for IA is ~3 years.25–28 Therefore, the 
time horizon (the duration of monitoring of the hypothetical 
patients of the model) of the presented model was 3.0 years 
(95% CI: 2.7–3.3 years; Table 1).
Presentation of results
The results are presented as average cost per life-year gained 
(LYG) by galactomannan-positive patients with IA treated 
with VOR+ANI and VOR monotherapy and as differences in 
costs and life-years between the two therapy strategies. Cost 
per LYG for VOR+ANI compared with VOR monotherapy was 
calculated. For the probabilistic analysis, cost-effectiveness 
planes were calculated and probability of cost-effectiveness 
estimated relative to local willingness-to-pay thresholds of 
€30,000 and €45,000 as previously reported.29,30
Results
Deterministic analysis
In each hypothetical cohort of 1,000 patients receiving either 
VOR+ANI combination therapy or VOR alone, 157 and 
273 deaths were expected to occur, respectively. In surviv-
ing patients, 256 and 274 AEs were predicted in patients 
Table 2 Drug acquisition cost calculation
Body weighta (kg) Item Day 1 Days 2–7 Days 2–14 Days 8–42 Total cost (€)
Voriconazole
70.0 Dose (mg/kg)b 840 560 – 600 –
Administrationc IV IV – Oral –
Cost (€)d 517.95 2,071.79 – 3,465.00 6,054.74
67.8 Dose (mg/kg)b 813 542 – 600 –
Administrationc IV IV – Oral –
Cost (€)d 501.37 2,005.48 – 3,465.00 5,971.86
76.1 Dose (mg/kg)b 914 609 – 600 –
Administrationc IV IV – Oral –
Cost (€)d 563.34 – 2,253.36 3,465.00 6,281.71
Anidulafungin
Any Dose (mg)b 200 – 100 –
Administrationc IV IV IV – –
Cost (€) 646.02 – 4,199.13 – 4,845.15
Notes: aBody weight in Spanish adults (70.0 kg; 95% CI: 67.76–76.13 kg) obtained from Spanish official figures16,39; bdoses calculated from Marr et al9; cobtained from Summary 
of Product Characteristics13; ddrug acquisition costs were obtained from the approved ex-factory prices in Spain with official 7.5% discount rate as of early 2016.13
Abbreviations: CI, confidence interval; IV, intravenous.
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receiving either VOR+ANI combination therapy or VOR 
alone, respectively. More serious AEs were expected with 
VOR+ANI (n=50) than with VOR monotherapy (n=39).
The median duration of VOR+ANI combination therapy 
was 14 days (range: 1–29 days); the median duration of VOR 
monotherapy was 42 days (range: 1–48 days).9 As shown in 
Table 3, the average life expectancy per patient was 2.5 years 
with VOR+ANI and 2.2 years with VOR monotherapy (an 
increase of 0.348 LYG with VOR+ANI). The average cost 
per patient of antifungal therapy for IA was €17,902 with 
VOR+ANI and €12,409 with VOR monotherapy (an additional 
cost of €5,493 with VOR+ANI). Consequently, the incremental 
cost per LYG was €15,785 with VOR+ANI versus VOR.
The results of the univariate sensitivity analyses are rep-
resented in the Tornado plot (Figure 2). The variables that 
most influenced the results were mortality probabilities for 
each of the compared therapy strategies. The variation in the 
mortality probability with VOR+ANI (0.10–0.24) would lead 
to a cost per LYG with VOR+ANI versus VOR monotherapy 
from €10,669 to €52,144. The variation in the mortality 
probability with VOR monotherapy (0.20–0.36) would lead 
to a cost per LYG with combination from €8,924 to €44,509 
(Figure 2). When the duration of antifungal therapy was 
varied by ±7 days relative to the base-case analysis, the cost 
per LYG was €9,287 with VOR+ANI versus €22,282 with 
VOR monotherapy.
Probabilistic analysis
In the probabilistic analysis, the cost per LYG with VOR+ANI 
was €15,774 (95% CI: €15,763–16,692; Table 4). The prob-
ability that VOR+ANI would be considered cost-effective 
compared with VOR was estimated at 82.5% and 91.9% at 
locally established willingness-to-pay thresholds of €30,000 
and €45,000, respectively (Figure 3). The cost-effectiveness 
acceptability curves for both therapy options are presented 
in Figure 4.
Discussion
The pharmacoeconomic model used in this study suggests an 
increase of 0.348 LYG with VOR+ANI compared with VOR 
monotherapy for galactomannan test-based IA in each patient 
with hematologic disease or HSCT. According to the study by 
Rodriguez-Tudela et al, there were 419 such patients across 
Spain in 2010.31 Therefore, widespread VOR+ANI combination 
therapy in patients with hematologic disease or HSCT in Spain 
could provide an annual gain of ~146 years compared with VOR 
monotherapy. Similarly, our findings suggest that the probability 
that VOR+ANI combination therapy of IA is cost-effective 
compared with VOR monotherapy is 82.5% at a previously 
established local willingness-to-pay threshold of €30,000 per 
LYG (91.9% at a threshold of €45,000 per LYG).29,30
Certain limitations and inconsistencies of this study must 
be taken into account when considering these results. This was 
a theoretical model, which, by definition, was a simulation of 
real-world clinical practice. Additionally, efficacy and AE data 
were obtained from an explanatory double-blind, randomized 
clinical trial (NCT00531479),9 as no data from pragmatic 
clinical trials were available.32 Consequently, the results of 
the economic analysis are applicable only to patients with 
similar characteristics to those included in that clinical trial. 
Also, the lower mortality of the subgroup of patients who 
received VOR+ANI combination therapy for IA indicated by 
galactomannan testing in the trial reported by Marr et al9 was 
determined by means of a post hoc analysis, with associated 
methodological limitations.33 As noted by Marr et al,9 further 
work is required to confirm the results obtained in the combi-
nation therapy subgroup; our economic model was, therefore, 
also dependent on such limitations. The highest mortality 
probabilities used in the deterministic sensitivity analyses 
with VOR+ANI and VOR monotherapy lead to costs per LYG 
with the combination above €30,000 per LYG.
Reliability of the presented findings were assessed by 
Monte Carlo simulation.34 In clinicoeconomic research, this 
statistical approach is used to predict individual clinical 
outcomes for a hypothetical cohort of patients using theo-
retical sampling of random variables, the behavior of which 
is described by means of given sampling distributions.35 
Therefore, the Monte Carlo simulation shows the effect of 
the random changes conducted on different parameters and 
consequently imitates the actual clinical development of the 
patients. The reliability of the result obtained was effectively 
confirmed by the sensitivity analyses conducted. Accord-
ing to our probabilistic sensitivity analysis, the probability 
of VOR+ANI being cost-effective compared with VOR 
Table 3 Deterministic analysis results: base-case
Treatment Costs (€) Cost differences (€) Life-years LYG Cost per LYGa (€)
VOR+ANI 17,902 5,493 2.529 0.348 15,785
VOR 12,409 2.181
Notes: aIncremental cost-effectiveness ratio (cost per LYG with VOR+ANI versus VOR monotherapy).
Abbreviations: ANI, anidulafungin; LYG, life-year gained; VOR, voriconazole.
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 monotherapy was 82.5% versus 91.9%, at local willingness-
to-pay thresholds of €30,000 and €45,000 per LYG, respec-
tively.29,30 All costs used in the model were taken from Spanish 
sources, to ensure that the results accurately reflected routine 
clinical practice in the Spanish healthcare system.
It was not possible to compare the results and procedures 
of this study with those from another country, as no similar 
economic analyses comparing VOR+ANI combination ther-
apy with VOR monotherapy for IA in galactomannan-positive 
patients were identified. Nor were any studies found that 
compared the efficacy of other antifungal therapy strategies in 
IA or in other indications in galactomannan-positive patients. 
In published studies, only the unit cost of the galactomannan 
test was assessed, and not its diagnostic role as a possible 
determinant of the cost-effectiveness of IA therapy.36,37 No 
costs were considered for additional diagnostic tests given 
as part of a full diagnostic workup or as follow-up to galac-
tomannan antigen testing, under the assumption that these 
costs would not be substantial.
Conclusion
On the basis of the findings of our economic model and 
probabilistic sensitivity analysis, combination therapy with 
VOR+ANI may be cost-effective as the primary therapy for 
IA in galactomannan-positive patients in Spain, compared 
with VOR monotherapy.
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Figure 3 Cost-effectiveness plane (Monte Carlo simulation) at: (A) a willingness-to-pay threshold of €30,000; and (B) a willingness-to-pay threshold of €45,000.
Abbreviations: ANI, anidulafungin; LYG, life-year gained; VOR, voriconazole; WTP, willingness-to-pay threshold.
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Figure 4 Cost-effectiveness acceptability curve.
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